Clinical outcomes and safety of zoledronic acid in castration-resistant metastatic prostate cancer with bone metastases: real-world data from Côte d’Ivoire

@article{odo2026clinical,
  title = {{Clinical outcomes and safety of zoledronic acid in castration-resistant metastatic prostate cancer with bone metastases: real-world data from Côte d’Ivoire}},
  author = {Bitti Addé Odo and Kouame Konan Yvon Kouassi and Pétiori Gningayou Laurence Toure and Gnakoury Alain Pacome Gnabro and Yenahaban Lazare Touré and Mohamed Kassir Agnide Madiou and Félix Mbarga Amougou and N'guessan Malan Prosper Mebiala and Fleur Audrey Sessegnon and Akissi Marie Barbara Yvonne Nogbou and Halourou Agrigna and Kalifa Sako and Moctar Toure and Innocent Adoubi},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1847737},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1847737/full},
  note = {CC BY 4.0},
}

TY  - JOUR
TI  - Clinical outcomes and safety of zoledronic acid in castration-resistant metastatic prostate cancer with bone metastases: real-world data from Côte d’Ivoire
AU  - Bitti Addé Odo
AU  - Kouame Konan Yvon Kouassi
AU  - Pétiori Gningayou Laurence Toure
AU  - Gnakoury Alain Pacome Gnabro
AU  - Yenahaban Lazare Touré
AU  - Mohamed Kassir Agnide Madiou
AU  - Félix Mbarga Amougou
AU  - N'guessan Malan Prosper Mebiala
AU  - Fleur Audrey Sessegnon
AU  - Akissi Marie Barbara Yvonne Nogbou
AU  - Halourou Agrigna
AU  - Kalifa Sako
AU  - Moctar Toure
AU  - Innocent Adoubi
PY  - 2026
DA  - 2026/10/26
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1847737
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1847737/full
AB  - Background: Zoledronic acid is used to prevent skeletal complications in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. Real world data on its use in resource-limited setting, particularly in sub-saharan Africa, remain scarce.  Aim: To describe clinical outcomes, skeletal-related events, safety and quality of life in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases treated with zoledronic acid in Côte d’Ivoire.  Methods: We conducted a retrospective, single center cohort study including 144 patients with mCRPC and bone metastases treated with zoledronic acid at Treichville university Hospital between January 2019 and December 2021. The primary endpoint was skeletal event-free survival (SEFS) defined as the time from the first zoledronic acid administration to the first on-treatment skeletal related event (SRE). Patients without an SRE were censored at their last available follow-up.  Results: The median age was 67 years (range: 42–91), and 133 patients (92.4%) were older than 50 years. Before zoledronic acid initiation, 59 patients (41.0%) had experienced at least one skeletal-related event. After treatment initiation, 30 patients (20.8%) experienced at least one new on-treatment SRE, whereas 114 (79.2%) did not. Among patients who experienced an SRE, the median time to the first event was 9 months (range 5-11). Median SEFS was not reached and the estimated 12-month SEFS was 79.2%. The most frequently documented adverse events were bone pain (18.8%), constipation (18.1%) and nausea (9.7%). FACT-G data at both baseline and 12-month were available for 129 patients (89.6%) and mean scores across all four FACT-G domains, as well as the total FACT-G score, were numerically lower at 12 months than at baseline.  Conclusion: In this retrospective cohort of patients with mCRPC and bone metastases, 20.8% experienced a new SRE after zoledronic acid initiation, while median SEFS was not reached. FACT-G scores decreased during follow-up. These findings provide real-world data on zoledronic acid use in a resource-limited setting.
SN  - 2234-943X
ER  -